Evaluation of the Efficacy and Prognosis of MRI Combined with miR-134 in Neo-adjuvant Chemotherapy Combined with Breast-conserving Surgery

Abstract

To explore the application effect of MRI and miR-134 in neo-adjuvant chemotherapy combined with breast-conserving surgery. Sixty-one patients who received neo-adjuvant chemotherapy combined with breast-conserving surgery were collected as observation group (OG), and other 53 patients who received breast-conserving surgery at the same time were collected as control group (CG). The positive surgical margins rate, axillary lymph node metastasis rate, 5-year survival rate, recurrence rate and miR-134 expression before and after treatment were compared between the two groups. The diagnostic ability of MRI and miR-134 before treatment for axillary lymph node metastasis and the prognostic significance of miR-134 after treatment were explored. The positive surgical margins rate in OG was obviously lower than that in CG. There was no significant difference in axillary lymph node metastasis rate. There was no obvious difference in 5-year survival rate in both groups. The 5-year recurrence rate in OG was obviously lower than that in CG. Before therapy, the area under ROC curve (AUC) of miR-134 in diagnosing axillary lymph node metastasis was 0.788, and the specificity and sensitivity were 70.59% and 86.25%. The specificity and sensitivity of MRI diagnosis were 90.00% and 76.47%, and the combined diagnosis was 63.75% and 97.06%, so the sensitivity was improved. After treatment, the AUC of miR-134 in predicting 5-year survival was 0.810, and that of miR-134 in predicting 5-year recurrence was 0.767. To sum up, neo-adjuvant chemotherapy combined with breast-conserving surgery can decline the postoperative recurrence rate of patients. Preoperative miR-134 combined with MRI can diagnose axillary lymph node metastasis, and preoperative miR-134 can predict the prognosis.